SUPRACOR for Myopia and Myopic Astigmatism

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2011 by Technolas Perfect Vision GmbH.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Technolas Perfect Vision GmbH
ClinicalTrials.gov Identifier:
NCT01404884
First received: July 27, 2011
Last updated: NA
Last verified: July 2011
History: No changes posted
  Purpose

This clinical study has been planned to evaluate the safety and effectiveness of the SUPRACR presbyopic excimer laser treatment algorithm for myopic eyes developed for applying to the cornea of the human eye in a single center.

The developed software algorithm uses the subjective refraction of the eye to create a treatment for the distance vision correction. This part of the treatment does not show any difference to a regular aspheric LASIK treatment for myopic cases.

In addition to the treatment for the distance vision an additional central ablation component will be added to address the near vision.

The study design is applied as a single center unilateral eye safety and effectiveness study of the SUPRACOR presbyopic algorithm for myopia with a 3 months postoperative follow up.


Condition Intervention Phase
Myopia
Myopic Astigmatism
Presbyopia
Procedure: SUPRACOR
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Prospective Study To Evaluate The Safety And Effectiveness Of The SUPRACOR Presbyopic Treatment Algorithm For Myopia And Myopic Astigmatism Using LASIK

Further study details as provided by Technolas Perfect Vision GmbH:

Primary Outcome Measures:
  • The percentage of treated eyes with a best corrected high contrast distance VA of 20/25 or better [ Time Frame: 3 Months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • The percentage of treated eyes within +/- 1.00D of target refraction [ Time Frame: 3 Months ] [ Designated as safety issue: No ]
  • The percentage of treated eyes within +/- 0.50D of target refraction [ Time Frame: 3 Months ] [ Designated as safety issue: No ]
  • The percentage of treated eyes with an uncorrected high contrast near VA of 20/40 or better [ Time Frame: 3 Months ] [ Designated as safety issue: No ]
  • Stability analysis: change of <1D MRSE between two consecutive post-op visits [ Time Frame: 3 Months ] [ Designated as safety issue: No ]
  • Loss of more than 2 lines in BCVA for distance vision [ Time Frame: 3 Months ] [ Designated as safety issue: Yes ]
  • The percentage of treated eyes with an induced subjective manifest refraction cylinder not within +/- 2.00D [ Time Frame: 3 Months ] [ Designated as safety issue: No ]
  • Cumulative incidence of AEs [ Time Frame: 3 Months ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 60
Study Start Date: June 2011
Estimated Study Completion Date: February 2012
Estimated Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SUPRACOR
Treatment arm consisting of patients with history of myopia or myopic astigmatism who are also diagnosed with presbyopia.
Procedure: SUPRACOR
The developed software algorithm uses the subjective refraction of the eye to create a treatment for the distance vision correction. In addition to the treatment for the distance vision an additional central ablation component will be added to address the near vision.
Other Name: PresbyLASIK

Detailed Description:

Presbyopia is an age-related progressive decrease in the ability to bring near objects to clear focus. It is attributed to changes in the accommodative apparatus in the visual system which includes the ciliary muscle and crystalline lens. Current Presbyopia management includes bifocal or multifocal corrections in spectacles or contact lenses that provide good focus over a range of object distances.

Current LASIK refractive surgery algorithms using Excimer laser are a safe, effective, and precise way to treat ametropia in eyes with regular corneas. The LASIK procedure uses a microkeratome to create a lamellar resection of the cornea at an intended depth ranging from 90 to 160 microns. The microkeratome is designed to maintain a "hinge" of tissue so that a flap of corneal epithelium and superficial stroma can be lifted to expose deeper stromal tissue while remaining attached to the cornea. The ablative energy of the excimer laser is then applied directly on the exposed corneal stroma to remove the required amount of tissue for a given refractive error. The amount of corneal tissue to be removed is determined by the magnitude of refractive correction and treatment area (optic zone). Once the laser ablation is completed, the flap is repositioned over the residual stromal bed.

The presbyopic treatment consists of a standard aspheric treatment for distance vision and the so called SUPRACOR addition to correct near vision.

The SUPRACOR addition provides a multifocal ablation with a central near addition with an aberration controlled transition zone towards the periphery, thereby allowing good focus over a range of object distances. This approach showed good near visual performance in hyperopic eyes (see also section 2.1).

The SUPRACOR presbyopic treatment algorithm subject to this study has been specifically developed to prospectively generate a treatment file for the Technolas 217z100 laser that will provide Presbyopia correction among eyes with primary myopia or myopic astigmatism (distance correction).

  Eligibility

Ages Eligible for Study:   45 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects must be at least 45 years old and not older than 85 years
  • Subjects must read, understand, and sign an Informed Consent Form (ICF).
  • Subjects must be willing and able to return for scheduled follow up examinations through 3 months after surgery.
  • Subjects must have up to -7.0 diopters (D) of absolute spherical myopia (not spherical equivalent), with up to -4.0 D of refractive astigmatism (NOT corneal astigmatism) by manifest subjective refraction. The spherical equivalent and must be no more than -9.0 D.
  • Subjects must have presbyopia as determined by an age-related need for optical aid(> +1.50 D) for reading with their best distance correction.
  • Subjects who have be screened successfully for acceptance of the SUPRACOR simulation
  • Subjects who are contact lens wearers must have gas permeable (GP) lenses discontinued for at least 3 weeks and soft lenses discontinued for at least 1 week prior to the preoperative evaluation in the eye to be treated.
  • High contrast, manifest, best spectacle-corrected logMAR distance visual acuity (VA) must be correctable to at least 0.0 (20/20 or 6/6) in both eyes.

Exclusion Criteria:

  • Subjects for whom the combination of their baseline corneal thickness and the planned operative parameters for the LASIK procedure would result in less than 250 microns of remaining corneal thickness below the flap postoperatively.
  • Subjects for whom the preoperative assessment of the ocular topography indicates that one or both eyes are not suitable candidates for treatment based upon the suggested computer-simulated treatment plan (e.G. Keratoconus).
  • Subjects with anterior segment pathology, including dry eye syndrome and cataracts which in the Investigator's opinion, would interfere with best spectacle-corrected VA (BSCVA) or a successful treatment.
  • Subjects who have undergone previous intraocular or corneal surgery of any kind, including any type of excimer laser surgery for either refractive or therapeutic purposes. Previous LASIK treatment and standard cataract surgery is not an exclusion criteria
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01404884

Locations
Spain
Instituto Oftalmologico Castanera Recruiting
Barcelona, Spain, 08006
Contact: Miriam Sorell    932 173 704    miriam.sorell@institutocastanera.com   
Principal Investigator: Jorge Castanera, M.D.         
Sponsors and Collaborators
Technolas Perfect Vision GmbH
Investigators
Principal Investigator: Jorge Castanera, M.D. Instituto Oftalmologico Castanera
  More Information

Publications:
Responsible Party: Dr. Gerhard Youssefi, VP Research & Clinical Operations, Technolas Perfect Vision, GmbH
ClinicalTrials.gov Identifier: NCT01404884     History of Changes
Other Study ID Numbers: 1105
Study First Received: July 27, 2011
Last Updated: July 27, 2011
Health Authority: Spain: Comité Ético de Investigación Clínica

Keywords provided by Technolas Perfect Vision GmbH:
myopia
astigmatism
presbyopia
SUPRACOR
multifocal

Additional relevant MeSH terms:
Astigmatism
Myopia
Presbyopia
Eye Diseases
Refractive Errors

ClinicalTrials.gov processed this record on October 22, 2014